Global availability of critical reagents for biologicals testing - Current status, challenges and possible solutions

On July 2, 2024, the International Alliance for Biological Standardization (IABS) and Humane Society International (HSI) co-hosted a webinar on the global availability and affordability of critical reagents for vaccine and biologics production. Despite growing support for non-animal testing, significant barriers remain, especially in low-income countries facing financial and supply chain challenges. This meeting showcased successful collaborations on reagent production and shared industry and regulatory perspectives. Key barriers included high reagent costs, import complexities, and the limited number of suppliers. Participants stressed the need for tailored risk-based testing, in-house assay validation, and stronger collaboration for standardised testing. The idea of regional hubs in Africa and Southeast Asia for reagent distribution was also discussed to address logistical challenges. A central theme was advocating reliance strategies, which promote shared regulatory assessments and resource optimisation, as demonstrated by the EU/EEA OCABR Network activities and South African-European laboratory collaborations. Difficulties facing smaller national control laboratories in meeting international standards were highlighted, along with the need for further innovation in non-animal-derived reagents to address these challenges. Participants stressed the importance of continued global collaboration and adopting reliance practices to improve access to critical reagents and ensure sustainability in biologics testing.

Authors

Institutions

Publication Details

Journal
Biologicals
Published
2025-03-22
DOI
https://doi.org/10.1016/j.biologicals.2025.101821
Primary Topic
Biosimilars and Bioanalytical Methods
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Global availability of critical reagents for biologicals testing - Current status, challenges and possible solutions

Laura Viviani, Sunil Goel, Mic McGoldrick, Esther Veronika Wenzel et al.
Biologicals
Biosimilars and Bioanalytical Methods
article

Global availability of critical reagents for biologicals testing - Current status, challenges and possible solutions

Laura Viviani, Sunil Goel, Mic McGoldrick, Esther Veronika Wenzel, Dean Smith, Quinton Meyer, Emmanuelle Coppens, Carmen Jungbaëck, Michelle Rubbrecht, Le Sun, K. Mahmood, Catherine Milne, Joris Vandeputte
article en

Abstract

On July 2, 2024, the International Alliance for Biological Standardization (IABS) and Humane Society International (HSI) co-hosted a webinar on the global availability and affordability of critical reagents for vaccine and biologics production. Despite growing support for non-animal testing, significant barriers remain, especially in low-income countries facing financial and supply chain challenges. This meeting showcased successful collaborations on reagent production and shared industry and regulatory perspectives. Key barriers included high reagent costs, import complexities, and the limited number of suppliers. Participants stressed the need for tailored risk-based testing, in-house assay validation, and stronger collaboration for standardised testing. The idea of regional hubs in Africa and Southeast Asia for reagent distribution was also discussed to address logistical challenges. A central theme was advocating reliance strategies, which promote shared regulatory assessments and resource optimisation, as demonstrated by the EU/EEA OCABR Network activities and South African-European laboratory collaborations. Difficulties facing smaller national control laboratories in meeting international standards were highlighted, along with the need for further innovation in non-animal-derived reagents to address these challenges. Participants stressed the importance of continued global collaboration and adopting reliance practices to improve access to critical reagents and ensure sustainability in biologics testing.

BiologicalsVol. 90
Merck & Co., Inc., Rahway, NJ, USA (United States) (US), Health Canada (CA), Program for Appropriate Technology in Health (US), Goethe-Institute United Kingdom (GB), University of the Free State (ZA), Sanofi (France) (FR), Serum Institute of India (India) (IN), AbMax AntibodyChina (China) (CN), International Alliance for Biological Standardization (CH), Amedes Genetics (Germany) (DE), Conseil de L'Europe (FR), KU Leuven (BE)
Openalex Percentile: Top 94%
Biosimilars and Bioanalytical Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.